Amber Salzman is the founder of Epic-Bio. Epic-Bio has raised $68M in total funding. Latest round: Series B. Backed by Ally Bridge Group, SOLVE FSHD.
Amber Salzman, Ph.D., is the Chief Executive Officer and director of Epicrispr Biotechnologies, a biotechnology company developing curative therapies through epigenetic editing. The company recently secured $68 million in Series B financing to advance its lead program, EPI-321, for facioscapulohumeral muscular dystrophy. Prior to Epicrispr, Dr. Salzman was president and CEO of Ohana Biosciences and Adverum Biotechnologies, and co-founder of Annapurna, SAS.
Full founder directory · Investor directory · Company funding database · Fundraising library